What is Cyted Health?
Cyted Health operates at the intersection of biotechnology and clinical diagnostics, focusing specifically on the detection and management of gastrointestinal conditions. Based in Cambridge, England, the company utilizes proprietary technology to streamline the diagnostic process, aiming to improve patient outcomes through early intervention and data-driven insights. By addressing the complexities of gastrointestinal health, Cyted Health provides a vital service to healthcare providers and patients alike, positioning itself as a leader in the digital health and diagnostics sector. Its market position is bolstered by a robust intellectual property portfolio and a commitment to clinical excellence, which has attracted significant interest from top-tier venture capital and private equity firms.
How much funding has Cyted Health raised?
Cyted Health has raised a total of $43.5M across 1 funding round:
Series B
$43.5M
Series B (2025): $43.5M with participation from BGF, EQT, Advent Life Sciences, The Morningside Group, and British Business Bank
Key Investors in Cyted Health
BGF
BGF is a prominent UK-based investment firm that provides growth capital to small and mid-sized businesses across various sectors, acting as a long-term partner for scaling enterprises.
EQT
EQT Group is a global investment organization that manages diverse strategies including private equity and venture capital, focusing on sustainable growth and operational excellence.
Advent Life Sciences
Advent Life Sciences is a specialized venture capital firm that partners with management teams to develop innovative medicines and medical products, with a strong focus on the life sciences sector.
What's next for Cyted Health?
Looking ahead, the strategic deployment of the $43.5M will likely focus on scaling operational capacity and expanding the reach of its diagnostic services. As the company transitions through this major enterprise-level funding phase, the focus will shift toward commercialization and the integration of its technology into broader healthcare systems. The involvement of seasoned investors suggests a clear path toward market leadership, with potential for international expansion and the development of new diagnostic modalities. Cyted Health is poised to leverage this financial backing to solidify its infrastructure, enhance its clinical validation studies, and ultimately transform the standard of care for patients suffering from gastrointestinal diseases.
See full Cyted Health company page
